0001209191-20-065602.txt : 20201230 0001209191-20-065602.hdr.sgml : 20201230 20201230210010 ACCESSION NUMBER: 0001209191-20-065602 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201228 FILED AS OF DATE: 20201230 DATE AS OF CHANGE: 20201230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROBINS CHAD M CENTRAL INDEX KEY: 0001780649 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 201427286 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-28 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780649 ROBINS CHAD M C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 1 1 0 0 CEO and Chairman Common Stock 2020-12-28 4 M 0 16250 0.33 A 1794430 D Common Stock 2020-12-28 4 S 0 13542 60.71 D 1780888 D Common Stock 2020-12-28 4 S 0 1108 61.48 D 1779780 D Common Stock 2020-12-28 4 S 0 1500 62.60 D 1778280 D Common Stock 2020-12-28 4 S 0 100 63.41 D 1778180 D Common Stock 2020-12-29 4 M 0 16790 0.33 A 1794970 D Common Stock 2020-12-29 4 S 0 8256 58.87 D 1786714 D Common Stock 2020-12-29 4 S 0 6834 59.42 D 1779880 D Common Stock 2020-12-29 4 S 0 1700 60.73 D 1778180 D Common Stock 2020-12-30 4 M 0 16520 0.33 A 1794700 D Common Stock 2020-12-30 4 S 0 7651 59.20 D 1787049 D Common Stock 2020-12-30 4 S 0 8869 59.65 D 1778180 D Stock Option (Right to Buy) 0.33 2020-12-28 4 M 0 16250 0.00 D 2021-12-20 Common Stock 16250 33310 D Stock Option (Right to Buy) 0.33 2020-12-29 4 M 0 16790 0.00 D 2021-12-20 Common Stock 16790 16520 D Stock Option (Right to Buy) 0.33 2020-12-30 4 M 0 16520 0.00 D 2021-12-20 Common Stock 16520 0 D These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.12 to 61.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.14 to 61.74, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.14 to 63.13, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.21 to 59.20, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.21 to 60.01, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.26 to 61.05, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.48 to 59.46, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.49 to 59.99, inclusive. The options are fully vested and exercisable. /s/ Chad M. Robins by Eric Billings, Attorney-in-Fact 2020-12-30